EUCTR2015-004863-35-FI进行中（未招募）1 期
A prospective phase II study to assess the minimal residual disease after ixazomib plus lenalidomide plus dexamethasone (IRd) treatment for newly diagnosed transplant eligible patients - NMSG#23/15 IRd
Hospital District of Helsinki and Uusimaa/Helsinki University Hospital HUS0 个研究点目标入组 120 人开始时间: 2016年6月17日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 120
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Newly diagnosed transplant eligible male or female multiple myeloma patients, 18-70 years of age, who have not received prior treatment for multiple myeloma. Symptomatic and measurable disease diagnosed by standard CRAB and SLIM-CRAB biomarker criteria. Voluntary informed consent. Negative pregnancy test.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 90
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 30
排除标准
- •Female patients who are lactating or pregnant. Major surgery or radiotherapy within 14 days before enrollment. Central nervous system involvement with myeloma. Active infection requiring systemic antibiotic therapy. Unablity to use thrombosis or herpes zoster prophylaxis or treatment. Grade 1 polyneuropathy with pain or worse.Plasma cell leukemia or amyloidosis. Patients who are not willing to adhere to the pregnant prevention program.
研究者
相似试验
进行中（未招募）
1 期
A study of ixazomib plus lenalidomide plus dexamethasoen (IRd) for newly diagnosed transplant-eligible myeloma patientsMultiple myeloma newly diagnosed transplant-eligible patientsMedDRA version: 21.0Level: LLTClassification code 10028228Term: Multiple myelomaSystem Organ Class: 100000004864EUCTR2015-004863-35-LTHelsinki University Hospital Comprehensive Cancer Center Hematology120
进行中（未招募）
1 期
A study of ixazomib plus lenalidomide plus dexamethasoen (IRd) for newly diagnosed transplant-eligible myeloma patientsEUCTR2015-004863-35-SEHelsinki University Hospital Comprehensive Cancer Center Hematology120
进行中（未招募）
1 期
A study of ixazomib plus lenalidomide plus dexamethasoen (IRd) for newly diagnosed transplant-eligible myeloma patientsMultiple myeloma newly diagnosed transplant-eligible patientsMedDRA version: 21.0Level: LLTClassification code 10028228Term: Multiple myelomaSystem Organ Class: 100000004864EUCTR2015-004863-35-NOHelsinki University Hospital Comprehensive Cancer Center Hematology120
招募中
2 期
A phase II study to evaluate the effectiveness of S-1 + Cetuximab for patients with advanced/recurrent colon cancer who cannot undergo intensive therapyadvanced/recurrent colon cancer patients with RAS wild-type tumors who cannot undergo intensive therapyJPRN-UMIN000018484HO HOKKAIDO CANCER CENTER Division of Gastroenterology57
已完成
2 期
A randomized phase II study for the evaluation of T cell depleted non-myeloablative allogeneic stem cell transplantation followed by early consolidation with lenalidomide or lenalidomide combined with bortezomib and subsequent DLI for patients with multiple myeloma in progression or relapse following first line therapyKahlers disease10035227Multiple MyelomaNL-OMON36688HOVO110